Innovation in cryopreservation is turning to biomimicry by modeling new solutions on proteins found in Arctic fish. These natural proteins protect cells by binding to and inhibiting the growth of damaging ice crystals. This mechanism offers a non-toxic alternative that can be replicated synthetically in molecules like peptoids.
Because residual DMSO is toxic to patients, causing symptoms from nausea to cardiovascular events, it must be washed away before infusion. This mandatory washing step adds complexity and time to the final product preparation and, crucially, creates an additional opportunity for microbial contamination in an otherwise sterile process.
Despite known toxicity and FDA concerns, DMSO remains the standard cryopreservative because of its extensive clinical history and the high cost required to validate alternatives. Established protocols, regulatory history, and economic advantages create a significant barrier to innovation, trapping the industry in a legacy solution.
Standard post-thaw viability tests are misleading for cell therapies. DMSO can cause profound, non-lethal damage by altering gene expression, inducing differentiation in stem cells, and impairing T-cell function. Cells may be 'alive' but therapeutically impotent, a risk not captured by simple viability metrics.
DMSO's toxicity extends to the epigenetic level with a paradoxical effect. It can upregulate enzymes that add methyl groups (hypermethylation), silencing genes, while also promoting enzymes that remove them (hypomethylation), activating others. This disruption creates widespread genomic instability with unknown long-term consequences for cell therapy products.